Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...

Scotiabank raised the firm’s price target on Apellis (APLS) to $31 from $30 and keeps a Sector Perform rating on the shares. The company ...

Apellis Pharmaceuticals APLS announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted and granted Priority Review designation ...

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Apellis Pharmaceuticals Inc (Symbol: APLS) entered into oversold territory, hitting an RSI ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Signaturefd LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 357.2% during the 4th ...

In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of ...

Last week, Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million ...